Tekla Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Tekla Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-66,688	Closed	-$901K	–	223
2020 Q4	$901K	Hold	66,688	–	–	0.03%	180
2020 Q3	$785K	Hold	66,688	–	–	0.03%	186
2020 Q2	$984K	Hold	66,688	–	–	0.04%	193
2020 Q1	$900K	Hold	66,688	–	–	0.04%	181
2019 Q4	$1.61M	Hold	66,688	–	–	0.06%	157
2019 Q3	$1.28M	Hold	66,688	–	–	0.06%	148
2019 Q2	$1.97M	Sell	66,688 -1,808	-3%	-$69.7K	0.08%	135
2019 Q1	$3.25M	Buy	68,496 +29,726	+77%	+$1.31M	0.13%	116
2018 Q4	$1.4M	Hold	38,770	–	–	0.06%	144
2018 Q3	$2.39M	Buy	+38,770	New	+$2.49M	0.09%	141

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Tekla Capital Management's AERI Position: Q1 2021 in Review

Tekla Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2021, closing a stake of 66,688 shares — an estimated $901K sold.

Tekla Capital Management first reported a position in AERI in Q3 2018 and held it in 10 quarters. The position peaked at $3.25M in Q1 2019. 158 funds tracked by Wall St. Rank hold AERI as of Q1 2021.

Tekla Capital Management reported no remaining Aerie Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 66,688 Aerie Pharmaceuticals shares in Q1 2021, an estimated $901K.
Tekla Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2018 and held it in 10 quarters.
Tekla Capital Management's Aerie Pharmaceuticals position peaked at $3.25M in Q1 2019.
158 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.